Crossmark Global Holdings’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.7M | Sell |
7,022
-2,772
| -28% | -$1.55M | 0.05% | 311 |
|
|
2026
Q1 | $5.5M | Buy |
9,794
+298
| +3% | +$191K | 0.08% | 242 |
|
|
2025
Q4 | $6.42M | Buy |
9,496
+5,927
| +166% | +$4.04M | 0.09% | 219 |
|
|
2025
Q3 | $2.28M | Buy |
3,569
+305
| +9% | +$185K | 0.03% | 411 |
|
|
2025
Q2 | $1.75M | Sell |
3,264
-504
| -13% | -$241K | 0.03% | 460 |
|
|
2025
Q1 | $1.58M | Buy |
3,768
+59
| +2% | +$25.6K | 0.03% | 476 |
|
|
2024
Q4 | $1.53M | Sell |
3,709
-865
| -19% | -$379K | 0.03% | 463 |
|
|
2024
Q3 | $2.31M | Sell |
4,574
-286
| -6% | -$139K | 0.04% | 378 |
|
|
2024
Q2 | $2.37M | Buy |
4,860
+40
| +0.8% | +$20.1K | 0.05% | 361 |
|
|
2024
Q1 | $2.6M | Buy |
4,820
+59
| +1% | +$32.2K | 0.05% | 355 |
|
|
2023
Q4 | $2.64M | Sell |
4,761
-294
| -6% | -$138K | 0.05% | 336 |
|
|
2023
Q3 | $2.28M | Buy |
5,055
+463
| +10% | +$231K | 0.05% | 356 |
|
|
2023
Q2 | $2.54M | Sell |
4,592
-95
| -2% | -$45.5K | 0.05% | 351 |
|
|
2023
Q1 | $2.34M | Sell |
4,687
-393
| -8% | -$188K | 0.06% | 357 |
|
|
2022
Q4 | $2.07M | Buy |
5,080
+505
| +11% | +$196K | 0.05% | 383 |
|
|
2022
Q3 | $1.49M | Sell |
4,575
-244
| -5% | -$89.6K | 0.04% | 441 |
|
|
2022
Q2 | $1.69M | Sell |
4,819
-40
| -0.8% | -$16.3K | 0.04% | 423 |
|
|
2022
Q1 | $2.66M | Buy |
4,859
+50
| +1% | +$26.3K | 0.06% | 325 |
|
|
2021
Q4 | $3.17M | Sell |
4,809
-3,600
| -43% | -$2.26M | 0.07% | 280 |
|
|
2021
Q3 | $5.23M | Sell |
8,409
-435
| -5% | -$292K | 0.12% | 184 |
|
|
2021
Q2 | $5.58M | Sell |
8,844
-642
| -7% | -$355K | 0.13% | 171 |
|
|
2021
Q1 | $4.64M | Sell |
9,486
-770
| -8% | -$386K | 0.12% | 192 |
|
|
2020
Q4 | $5.13M | Buy |
10,256
+2,869
| +39% | +$1.28M | 0.13% | 181 |
|
|
2020
Q3 | $2.9M | Sell |
7,387
-587
| -7% | -$217K | 0.08% | 258 |
|
|
2020
Q2 | $2.63M | Buy |
7,974
+40
| +0.5% | +$11.6K | 0.08% | 278 |
|
|
2020
Q1 | $1.92M | Buy |
7,934
+10
| +0.1% | +$2.61K | 0.07% | 294 |
|
|
2019
Q4 | $2.07M | Buy |
7,924
+1,403
| +22% | +$370K | 0.06% | 360 |
|
|
2019
Q3 | $1.77M | Sell |
6,521
-416
| -6% | -$116K | 0.05% | 391 |
|
|
2019
Q2 | $1.91M | Buy |
6,937
+2
| +0% | +$493 | 0.05% | 394 |
|
|
2019
Q1 | $1.55M | Sell |
6,935
-50
| -0.7% | -$10.3K | 0.04% | 447 |
|
|
2018
Q4 | $1.3M | Sell |
6,985
-3,818
| -35% | -$783K | 0.04% | 474 |
|
|
2018
Q3 | $2.7M | Sell |
10,803
-733
| -6% | -$178K | 0.07% | 321 |
|
|
2018
Q2 | $2.51M | Sell |
11,536
-443
| -4% | -$91.3K | 0.07% | 322 |
|
|
2018
Q1 | $2.29M | Sell |
11,979
-541
| -4% | -$99.8K | 0.06% | 377 |
|
|
2017
Q4 | $1.96M | Sell |
12,520
-4,223
| -25% | -$665K | 0.05% | 437 |
|
|
2017
Q3 | $2.6M | Buy |
+16,743
| New | +$2.65M | 0.07% | 344 |
|
|
2016
Q3 | $2.6M | Buy |
+16,743
| New | +$1.76M | 0.07% | 344 |
|
Other funds holding IDXX
Crossmark Global Holdings's IDXX Position: Q2 2026 in Review
Crossmark Global Holdings reduced its Idexx Laboratories (IDXX) stake by 28% in Q2 2026, selling an estimated $1.55M and leaving 7,022 shares worth $3.7M. The position accounts for 0.05% of the portfolio, ranked #311.
Crossmark Global Holdings first reported a position in IDXX in Q3 2016 and has held it in 37 quarters since. The position peaked at $6.42M in Q4 2025. 1,296 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Crossmark Global Holdings held 7,022 shares of Idexx Laboratories worth $3.7M as of Q2 2026.
- Crossmark Global Holdings sold 2,772 Idexx Laboratories shares in Q2 2026, an estimated $1.55M.
- Idexx Laboratories made up 0.05% of Crossmark Global Holdings's portfolio in Q2 2026, its #311 holding.
- Crossmark Global Holdings first reported a position in Idexx Laboratories in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's Idexx Laboratories position peaked at $6.42M in Q4 2025.
- 1,296 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.